Northeast Financial Consultants’s Ligand Pharmaceuticals LGND Stock Holding History

Northeast Financial Consultants’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$213K	Buy	+1,876	New	+$201K	0.01%	282
2025 Q1	–	Sell	-1,876	Closed	-$201K	–	287
2024 Q4	$201K	Buy	+1,876	New	+$212K	0.01%	278
2022 Q3	–	Sell	-4,416	Closed	-$245K	–	349
2022 Q2	$245K	Hold	4,416	–	–	0.02%	282
2022 Q1	$309K	Buy	4,416 +1,409	+47%	+$102K	0.02%	296
2021 Q4	$290K	Hold	3,007	–	–	0.02%	287
2021 Q3	$261K	Hold	3,007	–	–	0.02%	297
2021 Q2	$246K	Buy	+3,007	New	+$250K	0.02%	314
2020 Q3	–	Sell	-3,070	Closed	-$214K	–	308
2020 Q2	$214K	Buy	+3,070	New	+$195K	0.02%	259
2020 Q1	–	Sell	-3,070	Closed	-$200K	–	296
2019 Q4	$200K	Buy	+3,070	New	+$205K	0.02%	292
2019 Q3	–	Sell	-3,070	Closed	-$219K	–	327
2019 Q2	$219K	Hold	3,070	–	–	0.02%	295
2019 Q1	$241K	Buy	+3,070	New	+$233K	0.03%	268

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northeast Financial Consultants's LGND Position: Q2 2025 in Review

Northeast Financial Consultants opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2025: 1,876 shares worth $213K. The stake represents 0.01% of the portfolio and ranks #282 among its holdings. This is a return to the name: Northeast Financial Consultants previously reported a position in LGND as recently as Q4 2024.

Northeast Financial Consultants first reported a position in LGND in Q1 2019 and has held it in 11 quarters since. The position peaked at $309K in Q1 2022. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

Northeast Financial Consultants held 1,876 shares of Ligand Pharmaceuticals worth $213K as of Q2 2025.
Ligand Pharmaceuticals was a new Northeast Financial Consultants position in Q2 2025.
Ligand Pharmaceuticals made up 0.01% of Northeast Financial Consultants's portfolio in Q2 2025, its #282 holding.
Northeast Financial Consultants first reported a position in Ligand Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
Northeast Financial Consultants's Ligand Pharmaceuticals position peaked at $309K in Q1 2022.
271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.